Using the multiphase optimization strategy (MOST) to optimize an HIV care continuum intervention for vulnerable populations: a study protocol

Marya Viorst Gwadz, Linda M Collins, Charles M Cleland, Noelle R Leonard, Leo Wilton, Monica Gandhi, R Scott Braithwaite, David C Perlman, Alexandra Kutnick, Amanda S Ritchie, Marya Viorst Gwadz, Linda M Collins, Charles M Cleland, Noelle R Leonard, Leo Wilton, Monica Gandhi, R Scott Braithwaite, David C Perlman, Alexandra Kutnick, Amanda S Ritchie

Abstract

Background: More than half of persons living with HIV (PLWH) in the United States are insufficiently engaged in HIV primary care and not taking antiretroviral therapy (ART), mainly African Americans/Blacks and Hispanics. In the proposed project, a potent and innovative research methodology, the multiphase optimization strategy (MOST), will be employed to develop a highly efficacious, efficient, scalable, and cost-effective intervention to increase engagement along the HIV care continuum. Whereas randomized controlled trials are valuable for evaluating the efficacy of multi-component interventions as a package, they are not designed to evaluate which specific components contribute to efficacy. MOST, a pioneering, engineering-inspired framework, addresses this problem through highly efficient randomized experimentation to assess the performance of individual intervention components and their interactions. We propose to use MOST to engineer an intervention to increase engagement along the HIV care continuum for African American/Black and Hispanic PLWH not well engaged in care and not taking ART. Further, the intervention will be optimized for cost-effectiveness. A similar set of multi-level factors impede both HIV care and ART initiation for African American/Black and Hispanic PLWH, primary among them individual- (e.g., substance use, distrust, fear), social- (e.g., stigma), and structural-level barriers (e.g., difficulties accessing ancillary services). Guided by a multi-level social cognitive theory, and using the motivational interviewing approach, the study will evaluate five distinct culturally based intervention components (i.e., counseling sessions, pre-adherence preparation, support groups, peer mentorship, and patient navigation), each designed to address a specific barrier to HIV care and ART initiation. These components are well-grounded in the empirical literature and were found acceptable, feasible, and promising with respect to efficacy in a preliminary study.

Methods/design: Study aims are: 1) using a highly efficient fractional factorial experimental design, identify which of five intervention components contribute meaningfully to improvement in HIV viral suppression, and secondary outcomes of ART adherence and engagement in HIV primary care; 2) identify mediators and moderators of intervention component efficacy; and 3) using a mathematical modeling approach, build the most cost-effective and efficient intervention package from the efficacious components. A heterogeneous sample of African American/Black and Hispanic PLWH (with respect to age, substance use, and sexual minority status) will be recruited with a proven hybrid sampling method using targeted sampling in community settings and peer recruitment (N = 512).

Discussion: This is the first study to apply the MOST framework in the field of HIV prevention and treatment. This innovative study will produce a culturally based HIV care continuum intervention for the nation's most vulnerable PLWH, optimized for cost-effectiveness, and with exceptional levels of efficacy, efficiency, and scalability.

Trial registration: ClinicalTrials.gov, NCT02801747 , Registered June 8, 2016.

Keywords: African American; Antiretroviral initiation; Black; Disparities; HIV care; HIV care continuum; Hispanic; Intervention; MOST; Multiphase optimization strategy.

Figures

Fig. 1
Fig. 1
Conceptual model grounded in the theory of triadic influence and self determination theory
Fig. 2
Fig. 2
Conditions in the fractional factorial design
Fig. 3
Fig. 3
Sequence of HTH2-MOST study activities

References

    1. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, Wang L, Ou SS, Anderson M, McCauley M, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14(4):281–290. doi: 10.1016/S1473-3099(13)70692-3.
    1. Granich R, Williams B, Montaner J. Fifteen million people on antiretroviral treatment by 2015: treatment as prevention. Curr Opin HIV AIDS. 2013;8(1):41–49. doi: 10.1097/COH.0b013e32835b80dd.
    1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505. doi: 10.1056/NEJMoa1105243.
    1. Mayer KH. Introduction: linkage, engagement, and retention in HIV care: essential for optimal individual- and community-level outcomes in the era of highly active antiretroviral therapy. Clin Infect Dis. 2011;52(Suppl 2):S205–S207. doi: 10.1093/cid/ciq043.
    1. Montague BT, Vuylsteke B, Buve A. Sustainability of programs to reach high risk and marginalized populations living with HIV in resource limited settings: implications for HIV treatment and prevention. BMC Public Health. 2011;11:701. doi: 10.1186/1471-2458-11-701.
    1. Yehia BR, Fleishman JA, Metlay JP, Moore RD, Gebo KA. Sustained viral suppression in HIV-infected patients receiving antiretroviral therapy. JAMA. 2012;308(4):339–342. doi: 10.1001/jama.2012.5927.
    1. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800. doi: 10.1093/cid/ciq243.
    1. Nachega JB, Uthman OA, Del Rio C, Mugavero MJ, Rees H, Mills EJ. Addressing the Achilles' heel in the HIV care continuum for the success of a test-and-treat strategy to achieve an AIDS-free generation. Clin Infect Dis. 2014;59(Suppl 1):S21–S27. doi: 10.1093/cid/ciu299.
    1. Bradley H, Hall HI, Wolitski RJ, Van Handel MM, Stone AE, LaFlam M, Skarbinski J, Higa DH, Prejean J, Frazier EL, et al. Vital signs: HIV diagnosis, care, and treatment among persons living with HIV--United States, 2011. MMWR Morb Mortal Wkly Rep. 2014;63(47):1113–1117.
    1. Horstmann E, Brown J, Islam F, Buck J, Agins BD. Retaining HIV-infected patients in care: where are we? Where do we go from here? Clin Infect Dis. 2010;50(5):752–761.
    1. Mugavero MJ, Amico KR, Horn T, Thompson MA. The state of engagement in HIV care in the United States: from cascade to continuum to control. Clin Infect Dis. 2013;57(8):1164–1171. doi: 10.1093/cid/cit420.
    1. Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, Chiosi JJ, Weinstein MC, Hicks PL, Aaronson WH, Moore RD, et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis. 2009;49(10):1570–1578. doi: 10.1086/644772.
    1. Ribaudo HJ, Smith KY, Robbins GK, Flexner C, Haubrich R, Chen Y, Fischl MA, Schackman BR, Riddler SA, Gulick RM. Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis. Clin Infect Dis. 2013;57(11):1607–1617. doi: 10.1093/cid/cit595.
    1. Simard EP, Fransua M, Naishadham D, Jemal A. The influence of sex, race/ethnicity, and educational attainment on human immunodeficiency virus death rates among adults, 1993-2007. Arch Intern Med. 2012;172(20):1591–1598. doi: 10.1001/archinternmed.2012.4508.
    1. Cully JA, Mignogna J, Stanley MA, Davila J, Wear J, Amico KR, Giordano TP. Development and pilot testing of a standardized training program for a patient-mentoring intervention to increase adherence to outpatient HIV care. AIDS Patient Care STDs. 2012;26(3):165–172. doi: 10.1089/apc.2011.0248.
    1. Joy R, Druyts EF, Brandson EK, Lima VD, Rustad CA, Zhang W, Wood E, Montaner JS, Hogg RS. Impact of neighborhood-level socioeconomic status on HIV disease progression in a universal health care setting. J Acquir Immune Defic Syndr. 2008;47(4):500–505. doi: 10.1097/QAI.0b013e3181648dfd.
    1. Recsky MA, Brumme ZL, Chan KJ, Wynhoven B, Yip B, Dong WW, Heath KV, Montaner JS, Levy AR, Hogg RS, et al. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy. J Infect Dis. 2004;190(2):285–292. doi: 10.1086/422007.
    1. Giordano TP, Gifford AL, White AC, Jr, Suarez-Almazor ME, Rabeneck L, Hartman C, Backus LI, Mole LA, Morgan RO. Retention in care: a challenge to survival with HIV infection. Clin Infect Dis. 2007;44(11):1493–1499. doi: 10.1086/516778.
    1. Hall HI, Tang T, Westfall AO, Mugavero MJ. HIV care visits and time to viral suppression, 19 U.S. jurisdictions, and implications for treatment, prevention and the national HIV/AIDS strategy. PLoS One. 2013;8:e84318.
    1. Centers for Disease Control and Prevention: HIV in the United States: The stages of care. . Accessed 1 Dec 2014.
    1. Hall HI, Frazier EL, Rhodes P, Holtgrave DR, Furlow-Parmley C, Tang T, Gray KM, Cohen SM, Mermin J, Skarbinski J. Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med. 2013;173(14):1337–1344. doi: 10.1001/jamainternmed.2013.6841.
    1. Christopoulos KA, Das M, Colfax GN. Linkage and retention in HIV care among men who have sex with men in the United States. Clin Infect Dis. 2011;52(Suppl 2):S214–S222. doi: 10.1093/cid/ciq045.
    1. Adedinsewo DA, Wei SC, Robertson M, Rose C, Johnson CH, Dombrowski J, Skarbinski J. Timing of antiretroviral therapy initiation in a nationally representative sample of HIV-infected adults receiving medical care in the United States. AIDS Patient Care STDs. 2014;28(12):613–621. doi: 10.1089/apc.2014.0194.
    1. Allgood KL, Hunt B, Rucker MG. Black: White disparities in HIV mortality in the United States. J Racial Ethn Health Disparities. 1990;2015:1–8.
    1. Oramasionwu C, Bailey SC, Johnson TL, Mao L. Engagement in outpatient care for persons living with HIV in the United States. AIDS Res Hum Retrovir. 2015;31(2):177–182. doi: 10.1089/aid.2014.0049.
    1. Centers for Disease Control and Prevention: HIV in the United States: At A Glance. . Accessed 10 Oct 2014.
    1. Singh S, Bradley H, Hu X, Skarbinski J, Hall HI, Lansky A. Men living with diagnosed HIV who have sex with men: progress along the continuum of HIV care - United States, 2010. MMWR Morb Mortal Wkly Rep. 2014;63(38):829–833.
    1. National Institutes of Health, Office of AIDS Research: NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding. . Accessed 14 Aug 2015.
    1. The Office of National AIDS Policy: National HIV/AIDS Strategy for the United States: Updated to 2020. . Accessed 1 Dec 2015.
    1. Whiteside YO, Cohen SM, Bradley H, Skarbinski J, Hall HI, Lansky A, Centers for Disease Control and Prevention. Progress along the continuum of HIV care among blacks with diagnosed HIV- United States MMWR. Morb Mortal Wkly Rep 2014. 2010;63(5):85–89.
    1. Centers for Disease Control and Prevention: Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data—United States and 6 Dependent Areas—2011. In: HIV Surveillance Supplemental Report. vol. 18; 2013.
    1. Collins LM, Kugler KC, Gwadz MV. Optimization of multicomponent behavioral and biobehavioral interventions for the prevention and treatment of HIV/AIDS. AIDS Behav. 2015.
    1. Gwadz M, Applegate E, Cleland C, Leonard NR, Wolfe H, Salomon N, Belkin M, Riedel M, Banfield A, Sanfilippo L et al. HIV-infected individuals who delay, decline, or discontinue antiretroviral therapy: comparing clinic- and peer-recruited cohorts. Front Public Health. 2014;2(81).
    1. Gwadz M, Cleland CM, Applegate E, Belkin M, Gandhi M, Salomon N, Banfield A, Leonard N, Riedel M, Wolfe H, et al. Behavioral intervention improves treatment outcomes among HIV-infected individuals who have delayed, declined, or discontinued antiretroviral therapy: a randomized controlled trial of a novel intervention. AIDS Behav. 2015;19(10):1801–1817. doi: 10.1007/s10461-015-1054-6.
    1. Collins LM, Baker TB, Mermelstein RJ, Piper ME, Jorenby DE, Smith SS, Christiansen BA, Schlam TR, Cook JW, Fiore MC. The multiphase optimization strategy for engineering effective tobacco use interventions. Ann Behav Med. 2011;41(2):208–226. doi: 10.1007/s12160-010-9253-x.
    1. Collins LM, Dziak JJ, Li R. Design of experiments with multiple independent variables: a resource management perspective on complete and reduced factorial designs. Psychol Methods. 2009;14(3):202–224. doi: 10.1037/a0015826.
    1. Collins LM, Trail JB, Kugler KC, Baker TB, Piper ME, Mermelstein RJ. Evaluating individual intervention components: making decisions based on the results of a factorial screening experiment. Transl Behav Med. 2014;4(3):238–251. doi: 10.1007/s13142-013-0239-7.
    1. The Office of the Press Secretary, The White House: Executive Order: Accelerating Improvements in HIV Prevention and Care in the United States Through the HIV Care Continuum Initiative. . Accessed 11 Mar 2014.
    1. U.S. Department of Health and Human Services: National Institutes of Health Office of AIDS Research Web Site. . Accessed 11 Mar 2014.
    1. Flay BR, Snyder F, Petraitis J. The theory of triadic influence. In: DiClimente RJ, Kegler MC, Crosby RA, editors. Emerging theories in health promotion practice and research. New York: Jossey-Bass; 2009. p. 451–510.
    1. Deci EL, Ryan RM. The "what" and "why" of goal pursuits: human needs and the self-determination of behavior. Psychol Inq. 2000;11(4):227–268. doi: 10.1207/S15327965PLI1104_01.
    1. Vansteenkiste M, Sheldon KM. There's nothing more practical than a good theory: integrating motivational interviewing and self-determination theory. Br J Clin Psychol. 2006;45(1):63–82. doi: 10.1348/014466505X34192.
    1. Beer L, Fagan JL, Garland P, Valverde EE, Bolden B, Brady KA, Courogen M, Hillman D, Neaigus A, Bertolli J, et al. Medication-related barriers to entering HIV care. AIDS Patient Care STDs. 2012;26(4):214–221.
    1. Tobias CR, Cunningham W, Cabral HD, Cunningham CO, Eldred L, Naar-King S, Bradford J, Sohler NL, Wong MD, Drainoni ML. Living with HIV but without medical care: barriers to engagement. AIDS Patient Care STDs. 2007;21(6):426–434. doi: 10.1089/apc.2006.0138.
    1. van Ryn M. Research on the provider contribution to race/ethnicity disparities in medical care. Med Care. 2002;40(1 Suppl):I140–I151.
    1. Whetten K, Leserman J, Whetten R, Ostermann J, Thielman N, Swartz M, Stangl D. Exploring lack of trust in care providers and the government as a barrier to health service use. Am J Public Health. 2006;96(4):716–721. doi: 10.2105/AJPH.2005.063255.
    1. Bogart LM, Thorburn S. Are HIV/AIDS conspiracy beliefs a barrier to HIV prevention among African Americans? J Acquir Immune Defic Syndr. 2005;38(2):213–218. doi: 10.1097/00126334-200502010-00014.
    1. Udeagu CC, Webster TR, Bocour A, Michel P, Shepard CW. Lost or just not following up: public health effort to re-engage HIV-infected persons lost to follow-up into HIV medical care. AIDS. 2013;27(14):2271–2279. doi: 10.1097/QAD.0b013e328362fdde.
    1. Tugenberg T, Ware NC, Wyatt MA. Paradoxical effects of clinician emphasis on adherence to combination antiretroviral therapy for HIV/AIDS. AIDS Patient Care STDs. 2006;20(4):269–274. doi: 10.1089/apc.2006.20.269.
    1. Bogart LM, Wagner G, Galvan FH, Banks D. Conspiracy beliefs about HIV are related to antiretroviral treatment nonadherence among african american men with HIV. J Acquir Immune Defic Syndr. 2010;53(5):648–655.
    1. Sandelowski M, Voils CI, Chang Y, Lee EJ. A systematic review comparing antiretroviral adherence descriptive and intervention studies conducted in the USA. AIDS Care. 2009;21(8):953–966. doi: 10.1080/09540120802626212.
    1. Nordqvist O, Sodergard B, Tully MP, Sonnerborg A, Lindblad AK. Assessing and achieving readiness to initiate HIV medication. Patient Educ Couns. 2006;62(1):21–30. doi: 10.1016/j.pec.2005.09.014.
    1. Alfonso V, Bermbach N, Geller J, Montaner JS. Individual variability in barriers affecting people's decision to take HAART: a qualitative study identifying barriers to being on HAART. AIDS Patient Care STDs. 2006;20(12):848–857. doi: 10.1089/apc.2006.20.848.
    1. Gold RS, Hinchy J, Batrouney CG. The reasoning behind decisions not to take up antiretroviral therapy in Australians infected with HIV. Int J STD AIDS. 2000;11(6):361–370. doi: 10.1258/0956462001916065.
    1. Horne R, Cooper V, Gellaitry G, Date HL, Fisher M. Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the necessity-concerns framework. J Acquir Immune Defic Syndr. 2007;45(3):334–341.
    1. Kemppainen JK, Holzemer WL, Nokes K, Eller LS, Corless IB, Bunch EH, Kirksey KM, Goodroad BK, Portillo CJ, Chou FY. Self-care management of anxiety and fear in HIV disease. J Assoc Nurses AIDS Care. 2003;14(2):21–29. doi: 10.1177/1055329002250958.
    1. Turner MM. Using emotional appeals in health messages. In: Cho H, editor. Health Communication Message Design. Thousand Oaks: Sage Publications, Inc.; 2012. p. 59–73.
    1. Tegger MK, Crane HM, Tapia KA, Uldall KK, Holte SE, Kitahata MM. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care STDs. 2008;22(3):233–243. doi: 10.1089/apc.2007.0092.
    1. Meyer JP, Althoff AL, Altice FL. Optimizing care for HIV-infected people who use drugs: evidence-based approaches to overcoming healthcare disparities. Clin Infect Dis. 2013;57(9):1309–1317. doi: 10.1093/cid/cit427.
    1. Mimiaga MJ, Reisner SL, Grasso C, Crane HM, Safren SA, Kitahata MM, Schumacher JE, Mathews WC, Mayer KH. Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS research network of integrated clinical systems cohort. Am J Public Health. 2013;103(8):1457–1467. doi: 10.2105/AJPH.2012.301162.
    1. Gonzalez A, Mimiaga MJ, Israel J, Andres Bedoya C, Safren SA. Substance use predictors of poor medication adherence: the role of substance use coping among HIV-infected patients in opioid dependence treatment. AIDS Behav. 2013;17(1):168–173. doi: 10.1007/s10461-012-0319-6.
    1. Carrico AW, Riley ED, Johnson MO, Charlebois ED, Neilands TB, Remien RH, Lightfoot MA, Steward WT, Weinhardt LS, Kelly JA, et al. Psychiatric risk factors for HIV disease progression: the role of inconsistent patterns of antiretroviral therapy utilization. J Acquir Immune Defic Syndr. 2011;56(2):146–150. doi: 10.1097/QAI.0b013e318201df63.
    1. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(1):e1–34. doi: 10.1093/cid/cit665.
    1. Kim TW, Palepu A, Cheng DM, Libman H, Saitz R, Samet JH. Factors associated with discontinuation of antiretroviral therapy in HIV-infected patients with alcohol problems. AIDS Care. 2007;19(8):1039–1047. doi: 10.1080/09540120701294245.
    1. Li X, Margolick JB, Conover CS, Badri S, Riddler SA, Witt MD, Jacobson LP. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2005;38(3):320–328.
    1. Fagan JL, Beer L, Garland P, Valverde E, Courogen M, Hillman D, Brady K, Bertolli J. Never in care P. The influence of perceptions of HIV infection, care, and identity on care entry. AIDS Care. 2012;24(6):737–743. doi: 10.1080/09540121.2011.630360.
    1. Jenness SM, Myers JE, Neaigus A, Lulek J, Navejas M, Raj-Singh S. Delayed entry into HIV medical care after HIV diagnosis: risk factors and research methods. AIDS Care. 2012;24(10):1240–1248. doi: 10.1080/09540121.2012.656569.
    1. Fisher JD, Fisher WA, Amico KR, Harman JJ. An information-motivation-behavioral skills model of adherence to antiretroviral therapy. Health Psychol. 2006;25(4):462–473. doi: 10.1037/0278-6133.25.4.462.
    1. Wagner GJ, Lovely P, Schneider S. Pilot controlled trial of the adherence readiness program: an intervention to assess and sustain HIV antiretroviral adherence readiness. AIDS Behav. 2013;17(9):3059–3065. doi: 10.1007/s10461-013-0550-9.
    1. Waldrop-Valverde D, Guo Y, Ownby RL, Rodriguez A, Jones DL. Risk and protective factors for retention in HIV care. AIDS Behav. 2014;18(8):1483–1491. doi: 10.1007/s10461-013-0633-7.
    1. Catz SL, McClure JB, Jones GN, Brantley PJ. Predictors of outpatient medical appointment attendance among persons with HIV. AIDS Care. 1999;11(3):361–373. doi: 10.1080/09540129947983.
    1. Earnshaw VA, Bogart LM, Dovidio JF, Williams DR. Stigma and racial/ethnic HIV disparities: moving toward resilience. Am Psychol. 2013;68(4):225–236. doi: 10.1037/a0032705.
    1. Rao KC, Enriquez M, Gantt TC, Gerkovich MM, Bonham AJ, Griffin RG, Bamberger DM. Nonengagement in HIV care: a descriptive and qualitative study in hospitalized patients and community-based analysis. J Int Assoc Provid AIDS Care. 2013;12(3):178–184. doi: 10.1177/2325957412472058.
    1. Sayles JN, Wong MD, Kinsler JJ, Martins D, Cunningham WE. The association of stigma with self-reported access to medical care and antiretroviral therapy adherence in persons living with HIV/AIDS. J Gen Intern Med. 2009;24(10):1101–1108. doi: 10.1007/s11606-009-1068-8.
    1. Mugavero MJ, Norton WE, Saag MS. Health care system and policy factors influencing engagement in HIV medical care: piecing together the fragments of a fractured health care delivery system. Clin Infect Dis. 2011;52(Suppl 2):S238–S246. doi: 10.1093/cid/ciq048.
    1. Sumartojo E. Structural factors in HIV prevention: concepts, examples, and implications for research. AIDS. 2000;14(Suppl 1):S3–10. doi: 10.1097/00002030-200006001-00002.
    1. Aidala AA, Lee G, Abramson DM, Messeri P, Siegler A. Housing need, housing assistance, and connection to HIV medical care. AIDS Behav. 2007;11(6 Suppl):101–115. doi: 10.1007/s10461-007-9276-x.
    1. Des Jarlais DC. Structural interventions to reduce HIV transmission among injecting drug users. AIDS. 2000;14(Suppl 1):S41–S46. doi: 10.1097/00002030-200006001-00006.
    1. Cunningham WE, Andersen RM, Katz MH, Stein MD, Turner BJ, Crystal S, Zierler S, Kuromiya K, Morton SC, St Clair P, et al. The impact of competing subsistence needs and barriers on access to medical care for persons with human immunodeficiency virus receiving care in the United States. Med Care. 1999;37(12):1270–1281. doi: 10.1097/00005650-199912000-00010.
    1. Riley ED, Gandhi M, Hare C, Cohen J, Hwang S. Poverty, unstable housing, and HIV infection among women living in the United States. Curr HIV/AIDS Rep. 2007;4(4):181–186. doi: 10.1007/s11904-007-0026-5.
    1. Ickovics JR, Meade CS. Adherence to HAART among patients with HIV: breakthroughs and barriers. AIDS Care. 2002;14(3):309–318. doi: 10.1080/09540120220123685.
    1. Craw JA, Gardner LI, Marks G, Rapp RC, Bosshart J, Duffus WA, Rossman A, Coughlin SL, Gruber D, Safford LA, et al. Brief strengths-based case management promotes entry into HIV medical care: results of the antiretroviral treatment access study-II. J Acquir Immune Defic Syndr. 2008;47(5):597–606. doi: 10.1097/QAI.0b013e3181684c51.
    1. Hettema J, Steele J, Miller WR. Motivational interviewing. Annu Rev Clin Psychol. 2005;1:91–111. doi: 10.1146/annurev.clinpsy.1.102803.143833.
    1. Miller WR, Rollnick S. Motivational interviewing: helping people change. 3. New York, NY: Guilford Press; 2012.
    1. DiMatteo MR. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol. 2004;23(2):207–218. doi: 10.1037/0278-6133.23.2.207.
    1. Centers for Disease Control and Prevention. HIV Surveillance Report. In., vol. 25; 2013.
    1. Wohl AR, Galvan FH, Carlos JA, Myers HF, Garland W, Witt MD, Cadden J, Operskalski E, Jordan W, George S. A comparison of MSM stigma, HIV stigma and depression in HIV-positive Latino and African American men who have sex with men (MSM) AIDS Behav. 2013;17(4):1454–1464. doi: 10.1007/s10461-012-0385-9.
    1. Rao D, Feldman BJ, Fredericksen RJ, Crane PK, Simoni JM, Kitahata MM, Crane HM. A structural equation model of HIV-related stigma, depressive symptoms, and medication adherence. AIDS Behav. 2012;16(3):711–716. doi: 10.1007/s10461-011-9915-0.
    1. Semple SJ, Strathdee SA, Zians J, Patterson TL. Factors associated with experiences of stigma in a sample of HIV-positive, methamphetamine-using men who have sex with men. Drug Alcohol Depend. 2012;125(1–2):154–159. doi: 10.1016/j.drugalcdep.2012.04.007.
    1. Emlet CA, Fredriksen-Goldsen KI, Kim HJ, Hoy-Ellis C. The relationship between sexual minority stigma and sexual health risk behaviors among HIV-positive older gay and bisexual men. J Appl Gerontol. 2015:1–22.
    1. DeLorenze GN, Tsai AL, Horberg MA, Quesenberry CP., Jr Cost of care for HIV-infected patients with co-occurring substance use disorder or psychiatric disease: report from a large, integrated health plan. AIDS Res Treat. 2014;2014:570546.
    1. Abuse S, Administration MHS. Center for behavioral health statistics and quality. HIV/AIDS and Substance Use. In. Rockville, MD: THE NSDUH Report; 2010.
    1. Rosen MI, Black AC, Arnsten JH, Goggin K, Remien RH, Simoni JM, Golin CE, Bangsberg DR, Liu H. Association between use of specific drugs and antiretroviral adherence: findings from MACH 14. AIDS Behav. 2013;17(1):142–147. doi: 10.1007/s10461-011-0124-7.
    1. Kalichman SC, Kalichman MO, Cherry C, Hoyt G, Washington C, Grebler T, Welles B, Merely C. Intentional medication nonadherence because of interactive toxicity beliefs among HIV-positive active drug users. J Acquir Immune Defic Syndr. 2015;70(5):503–509. doi: 10.1097/QAI.0000000000000776.
    1. Malta M, Magnanini MM, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav. 2010;14(4):731–747. doi: 10.1007/s10461-008-9489-7.
    1. Azar P, Wood E, Nguyen P, Luma M, Montaner J, Kerr T, Milloy MJ. Drug use patterns associated with risk of non-adherence to antiretroviral therapy among HIV-positive illicit drug users in a Canadian setting: a longitudinal analysis. BMC Infect Dis. 2015;15:193. doi: 10.1186/s12879-015-0913-0.
    1. Binford MC, Kahana SY, Altice FL. A systematic review of antiretroviral adherence interventions for HIV-infected people who use drugs. Curr HIV/AIDS Rep. 2012;9(4):287–312. doi: 10.1007/s11904-012-0134-8.
    1. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies--tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–2066. doi: 10.1056/NEJMp1402780.
    1. Durvasula R, Miller TR. Substance abuse treatment in persons with HIV/AIDS: challenges in managing triple diagnosis. Behav Med. 2014;40(2):43–52. doi: 10.1080/08964289.2013.866540.
    1. Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–387. doi: 10.1016/S0140-6736(10)60829-X.
    1. Safren SA, O'Cleirigh CM, Bullis JR, Otto MW, Stein MD, Pollack MH. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol. 2012;80(3):404–415. doi: 10.1037/a0028208.
    1. Gardner LI, Giordano TP, Marks G, Wilson TE, Craw JA, Drainoni ML, Keruly JC, Rodriguez AE, Malitz F, Moore RD, et al. Enhanced personal contact with HIV patients improves retention in primary care: a randomized trial in 6 US HIV clinics. Clin Infect Dis. 2014;59(5):725–734. doi: 10.1093/cid/ciu357.
    1. Gandhi M, Ameli N, Bacchetti P, Gange SJ, Anastos K, Levine A, Hyman CL, Cohen M, Young M, Huang Y, et al. Protease inhibitor levels in hair samples strongly predict virologic responses to HIV treatment. AIDS. 2009;23(4):471–478. doi: 10.1097/QAD.0b013e328325a4a9.
    1. Insight Start Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;
    1. Department of Health and Human Services: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. . Accessed 25 Sept 2014.
    1. Heckathorn DD. Respondent-driven sampling: a new approach to the study of hidden populations. Soc Probl. 1997;44(2):174–199. doi: 10.2307/3096941.
    1. Heckman J. The common structure of statistical models of truncation, sample selection and limited dependent variable and a simple estimator for such models. Ann Econ Soc Meas. 1976;5(4):475–492.
    1. U. S. Department of Health Resources and Human Services Administration: Preparing people for treatment success. .
    1. Department of Health and Human Services: Adherence to Antiretroviral Therapy. . Accessed 20 Nov 2014.
    1. Rueda S, Park-Wyllie LY, Bayoumi AM, Tynan AM, Antoniou TA, Rourke SB, Glazier RH. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev. 2006:CD001442.
    1. Magidson JF, Blashill AJ, Safren SA, Wagner GJ. Depressive symptoms, lifestyle structure, and ART adherence among HIV-infected individuals: a longitudinal mediation analysis. AIDS Behav. 2015;19(1):34–40. doi: 10.1007/s10461-014-0802-3.
    1. Vaughan C, Wagner G, Miyashiro L, Ryan G, Scott JD. The role of the home environment and routinization in ART adherence. J Int Assoc Physicians AIDS Care (Chic) 2011;10(3):176–182. doi: 10.1177/1545109711399365.
    1. Health Resources and Services Administration - HIV/AIDS Bureau. Section 4: HIV Treatment. In: Guide for HIV/AIDS clinical care. AETC National Resource Center; 2014.
    1. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, Moss A. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181–3. doi: 10.1097/00002030-200106150-00015.
    1. Bandura A. Social learning theory. Englewood Cliffs: Prentice-Hall; 1977.
    1. Higa DH, Marks G, Crepaz N, Liau A, Lyles CM. Interventions to improve retention in HIV primary care: a systematic review of U.S. studies. Curr HIV/AIDS Rep. 2012;9(4):313–325. doi: 10.1007/s11904-012-0136-6.
    1. Nyamathi A, Flaskerud JH, Leake B, Dixon EL, Lu A. Evaluating the impact of peer, nurse case-managed, and standard HIV risk-reduction programs on psychosocial and health-promoting behavioral outcomes among homeless women. Res Nurs Health. 2001;24(5):410–422. doi: 10.1002/nur.1041.
    1. Purcell DW, Latka MH, Metsch LR, Latkin CA, Gomez CA, Mizuno Y, Arnsten JH, Wilkinson JD, Knight KR, Knowlton AR, et al. Results from a randomized controlled trial of a peer-mentoring intervention to reduce HIV transmission and increase access to care and adherence to HIV medications among HIV-seropositive injection drug users. J Acquir Immune Defic Syndr. 2007;46(Suppl 2):S35–S47. doi: 10.1097/QAI.0b013e31815767c4.
    1. Davey-Rothwell MA, Tobin K, Yang C, Sun CJ, Latkin CA. Results of a randomized controlled trial of a peer mentor HIV/STI prevention intervention for women over an 18 month follow-up. AIDS Behav. 2011;15(8):1654–1663. doi: 10.1007/s10461-011-9943-9.
    1. Simoni JM, Huh D, Frick PA, Pearson CR, Andrasik MP, Dunbar PJ, Hooton TM. Peer support and pager messaging to promote antiretroviral modifying therapy in Seattle: a randomized controlled trial. J Acquir Immune Defic Syndr. 2009;52(4):465–473. doi: 10.1097/QAI.0b013e3181b9300c.
    1. Simoni JM, Nelson KM, Franks JC, Yard SS, Lehavot K. Are peer interventions for HIV efficacious? A systematic review. AIDS Behav. 2011;15(8):1589–1595. doi: 10.1007/s10461-011-9963-5.
    1. Peer Center: Building Blocks to Peer Success. A Toolkit for Training HIV-Positive Peers. . Accessed 24 July 2014.
    1. Harris GE, Larsen D. HIV peer counseling and the development of hope: perspectives from peer counselors and peer counseling recipients. AIDS Patient Care STDs. 2007;21(11):843–860. doi: 10.1089/apc.2006.0207.
    1. Gonzalez JS, Penedo FJ, Antoni MH, Duran RE, McPherson-Baker S, Ironson G, Isabel Fernandez M, Klimas NG, Fletcher MA, Schneiderman N. Social support, positive states of mind, and HIV treatment adherence in men and women living with HIV/AIDS. Health Psychol. 2004;23(4):413–418. doi: 10.1037/0278-6133.23.4.413.
    1. Holt-Lunstad J, Smith TB, Layton JB. Social relationships and mortality risk: a meta-analytic review. PLoS Med. 2010;7(7) doi: 10.1371/journal.pmed.1000316.
    1. Spirig R. Support groups for people living with HIV/AIDS: a review of literature. J Assoc Nurses AIDS Care. 1998;9(4):43–55. doi: 10.1016/S1055-3290(98)80044-7.
    1. Greysen SR, Horwitz LI, Covinsky KE, Gordon K, Ohl ME, Justice AC. Does social isolation predict hospitalization and mortality among HIV+ and uninfected older veterans? J Am Geriatr Soc. 2013;61(9):1456–1463. doi: 10.1111/jgs.12410.
    1. Grov C, Golub SA, Parsons JT, Brennan M, Karpiak SE. Loneliness and HIV-related stigma explain depression among older HIV-positive adults. AIDS Care. 2010;22(5):630–639. doi: 10.1080/09540120903280901.
    1. Taylor SE. Social support: a review. In: Friedman HS, editor. Oxford Handbook of Health Psychology. New York: Oxford University Press; 2011.
    1. Lehavot K, Huh D, Walters KL, King KM, Andrasik MP, Simoni JM. Buffering effects of general and medication-specific social support on the association between substance use and HIV medication adherence. AIDS Patient Care STDs. 2011;25(3):181–189.
    1. Simoni JM, Pantalone DW, Plummer MD, Huang B. A randomized controlled trial of a peer support intervention targeting antiretroviral medication adherence and depressive symptomatology in HIV-positive men and women. Health Psychol. 2007;26(4):488–495. doi: 10.1037/0278-6133.26.4.488.
    1. Brashers DE, Neidig JL, Goldsmith DJ. Social support and the management of uncertainty for people living with HIV or AIDS. Health Commun. 2004;16(3):305–331. doi: 10.1207/S15327027HC1603_3.
    1. Rao D, Kekwaletswe TC, Hosek S, Martinez J, Rodriguez F. Stigma and social barriers to medication adherence with urban youth living with HIV. AIDS Care. 2007;19(1):28–33. doi: 10.1080/09540120600652303.
    1. Holstad MM, DiIorio C, Kelley ME, Resnicow K, Sharma S. Group motivational interviewing to promote adherence to antiretroviral medications and risk reduction behaviors in HIV infected women. AIDS Behav. 2011;15(5):885–896. doi: 10.1007/s10461-010-9865-y.
    1. Brewer RA, Magnus M, Kuo I, Wang L, Liu TY, Mayer KH. Exploring the relationship between incarceration and HIV among black men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2014;65(2):218–225. doi: 10.1097/01.qai.0000434953.65620.3d.
    1. Bradford JB, Coleman S, Cunningham W. HIV system navigation: an emerging model to improve HIV care access. AIDS Patient Care STDs. 2007;21(Suppl 1):S49–S58.
    1. Andersen M, Hockman E, Smereck G, Tinsley J, Milfort D, Wilcox R, Smith T, Connelly C, Adams L, Thomas R. The journal of the Association of Nurses in AIDS care: JANAC. J Assoc Nurses AIDS Care. 2007;18(3):33–41. doi: 10.1016/j.jana.2007.03.007.
    1. Koester KA, Morewitz M, Pearson C, Weeks J, Packard R, Estes M, Tulsky J, Kang-Dufour MS, Myers JJ. Patient navigation facilitates medical and social services engagement among HIV-infected individuals leaving jail and returning to the community. AIDS Patient Care STDs. 2014;28(2):82–90. doi: 10.1089/apc.2013.0279.
    1. Mugavero MJ. Improving engagement in HIV care: what can we do? Top HIV Med. 2008;16(5):156–161.
    1. Gwadz MV, Leonard NR, Cleland CM, Riedel M, Banfield A, Mildvan D. ACT2 project collaborative research team. The effect of peer-driven intervention on rates of screening for AIDS clinical trials among African Americans and Hispanics. Am J Public Health. 2011;101(6):1096–1102. doi: 10.2105/AJPH.2010.196048.
    1. New York City Department of Health and Mental Hygiene (NYCDOH): New York City HIV/AIDS Annual Surveillance Statistics, 2007. . Accessed 17 Oct 2008.
    1. New York State Department of Health. HIV Care in New York State: Linkage, Retention and Success, 2012. AIDS Institute; 2014.
    1. New York City Department of Health and Mental Hygiene: Care and clinical status of persons with HIV/AIDS in NYC in 2013 as based on HIV surveillance data. . Accessed 16 Nov 2014.
    1. Collins LM, Dziak JJ, Kugler KC, Trail JB. Factorial experiments: efficient tools for optimizing multicomponent interventions. Am J Prev Med. 2014;47(4):498–504. doi: 10.1016/j.amepre.2014.06.021.
    1. Collins LM, Murphy SA, Bierman KL. A conceptual framework for adaptive preventive interventions. Prev Sci. 2004;5(3):185–196. doi: 10.1023/B:PREV.0000037641.26017.00.
    1. Wu CJ, Hamada MS. Experiments: planning, analysis, and optimization. 2. New York: Wiley; 2009.
    1. SAS Institute Inc. SAS/QC® 13.2 User’s Guide. Cary: SAS Institute Inc.; 2014.
    1. Tsai AC, Karasic DH, Hammer GP, Charlebois ED, Ragland K, Moss AR, Sorensen JL, Dilley JW, Bangsberg DR. Directly observed antidepressant medication treatment and HIV outcomes among homeless and marginally housed HIV-positive adults: a randomized controlled trial. Am J Public Health. 2013;103(2):308–315. doi: 10.2105/AJPH.2011.300422.
    1. Gwadz M, Cleland CM, Belkin M, Ritchie A, Leonard N, Riedel M, Banfield A, Colon P, Elharrar V, Kagan J, et al. ACT2 peer-driven intervention increases enrollment into HIV/AIDS medical studies among African Americans/blacks and Hispanics: a cluster randomized controlled trial. AIDS Behav. 2014;18(12):2409–2422. doi: 10.1007/s10461-014-0829-5.
    1. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005;39(4):446–453. doi: 10.1097/01.qai.0000151079.33935.79.
    1. Iguchi MY, Ober AJ, Berry SH, Fain T, Heckathorn DD, Gorbach PM, Heimer R, Kozlov A, Ouellet LJ, Shoptaw S, et al. Simultaneous recruitment of drug users and men who have sex with men in the United States and Russia using respondent-driven sampling: sampling methods and implications. J Urban Health. 2009;86:S5–S31. doi: 10.1007/s11524-009-9365-4.
    1. Hightow-Weidman LB, Smith JC, Valera E, Matthews DD, Lyons P. Keeping them in "STYLE": finding, Linking, and retaining Young HIV-positive black and Latino men who have sex with men in care. Aids Patient Care St. 2011;25(1):37–45. doi: 10.1089/apc.2010.0192.
    1. Bonevski B, Randell M, Paul C, Chapman K, Twyman L, Bryant J, Brozek I, Hughes C. Reaching the hard-to-reach: a systematic review of strategies for improving health and medical research with socially disadvantaged groups. BMC Med Res Methodol. 2014;14:42. doi: 10.1186/1471-2288-14-42.
    1. Johnston LG, Whitehead S, Simic-Lawson M, Kendall C. Formative research to optimize respondent-driven sampling surveys among hard-to-reach populations in HIV behavioral and biological surveillance: lessons learned from four case studies. AIDS Care. 2010;22(6):784–792. doi: 10.1080/09540120903373557.
    1. Rudolph AE, Crawford ND, Latkin C, Heimer R, Benjamin EO, Jones KC, Fuller CM. Subpopulations of illicit drug users reached by targeted street outreach and respondent-driven sampling strategies: implications for research and public health practice. Ann Epidemiol. 2011;21(4):280–289. doi: 10.1016/j.annepidem.2010.11.007.
    1. Mugavero MJ, Westfall AO, Cole SR, Geng EH, Crane HM, Kitahata MM, Mathews WC, Napravnik S, Eron JJ, Moore RD, et al. Beyond core indicators of retention in HIV care: missed clinic visits are independently associated with all-cause mortality. Clin Infect Dis. 2014;59(10):1471–1479. doi: 10.1093/cid/ciu603.
    1. Dohrenwend BP, Shrout PE, Egri G, Mendelsohn FS. Nonspecific psychological distress and other dimensions of psychopathology. Measures for use in the general population. Arch Gen Psychiatry. 1980;37(11):1229–1236. doi: 10.1001/archpsyc.1980.01780240027003.
    1. Cook TD, Campbell DT. Quasi-experimentation: Design & Analysis Issues for field settings. 1. Boston: Houghton Mifflin; 1979.
    1. Hintze J. PASS 12. Kaysville: NCSS, LLC; 2013.
    1. Parienti JJ, Ragland K, Lucht F, de la Blanchardiere A, Dargere S, Yazdanpanah Y, Dutheil JJ, Perre P, Verdon R, Bangsberg DR, et al. Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication. Clin Infect Dis. 2010;50(8):1192–1197. doi: 10.1086/651419.
    1. Gandhi M, Ameli N, Bacchetti P, Anastos K, Gange SJ, Minkoff H, Young M, Milam J, Cohen MH, Sharp GB, et al. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis. 2011;52(10):1267–1275. doi: 10.1093/cid/cir131.
    1. Van Zyl GU, Van Mens TE, McIlleron H, Zeier M, Nachega JB, Decloedt E, Malavazzi C, Smith P, Huang Y, Van der Merwe L, et al. Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr. 2011;56(4):333–339. doi: 10.1097/QAI.0b013e31820dc0cc.
    1. Liu AY, Yang Q, Huang Y, Bacchetti P, Anderson PL, Jin C, Goggin K, Stojanovski K, Grant R, Buchbinder SP, et al. Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP) PLoS One. 2014;9(1) doi: 10.1371/journal.pone.0083736.
    1. Huang Y, Gandhi M, Greenblatt RM, Gee W, Lin ET, Messenkoff N. Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;22(21):3401–3409. doi: 10.1002/rcm.3750.
    1. Huang Y, Yang Q, Yoon K, Lei Y, Shi R, Gee W, Lin ET, Greenblatt RM, Gandhi M. Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2011;401(6):1923–1933. doi: 10.1007/s00216-011-5278-7.
    1. Gandhi M, Mwesigwa J, Aweeka F, Plenty A, Charlebois E, Ruel TD, Huang Y, Clark T, Ades V, Natureeba P, et al. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J Acquir Immune Defic Syndr. 2013;63(5):578–584. doi: 10.1097/QAI.0b013e31829c48ad.
    1. DiFrancesco R, Tooley K, Rosenkranz SL, Siminski S, Taylor CR, Pande P, Morse GD. Clinical pharmacology quality assurance for HIV and related infectious diseases research. Clin Pharmacol Ther. 2013;93(6):479–482. doi: 10.1038/clpt.2013.62.
    1. Baxi SM, Greenblatt RM, Bacchetti P, Jin C, French AL, Keller MJ, Augenbraun MH, Gange SJ, Liu C, Mack WJ, et al. Nevirapine concentration in hair samples is a strong predictor of Virologic suppression in a prospective cohort of HIV-infected patients. PLoS One. 2015;10(6) doi: 10.1371/journal.pone.0129100.
    1. Gandhi M, Greenblatt RM, Bacchetti P, Jin C, Huang Y, Anastos K, Cohen M, Dehovitz JA, Sharp GB, Gange SJ, et al. A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women. J Infect Dis. 2012;206(9):1453–1461. doi: 10.1093/infdis/jis508.
    1. Hickey MD, Salmen CR, Tessler RA, Omollo D, Bacchetti P, Magerenge R, Mattah B, Salmen MR, Zoughbie D, Fiorella KJ, et al. Antiretroviral concentrations in small hair samples as a feasible marker of adherence in rural Kenya. J Acquir Immune Defic Syndr. 2014;66(3):311–315. doi: 10.1097/QAI.0000000000000154.
    1. Collins LM, Graham JW. The effect of the timing and spacing of observations in longitudinal studies of tobacco and other drug use: temporal design considerations. Drug Alcohol Depend. 2002;68(Suppl 1):S85–S96. doi: 10.1016/S0376-8716(02)00217-X.
    1. French MT, Dunlap LJ, Zarkin GA, McGeary KA, McLellan AT. A structured instrument for estimating the economic cost of drug abuse treatment. The drug abuse treatment cost analysis program (DATCAP) J Subst Abus Treat. 1997;14(5):445–455. doi: 10.1016/S0740-5472(97)00132-3.
    1. Little RJA, Rubin DB. Statistical analysis with missing data. 2. Hoboken: Wiley; 2002.
    1. Dicicco-Bloom B, Crabtree BF. The qualitative research interview. Med Educ. 2006;40(4):314–321. doi: 10.1111/j.1365-2929.2006.02418.x.
    1. Jo B. Statistical power in randomized intervention studies with noncompliance. Psychol Methods. 2002;7(2):178–193. doi: 10.1037/1082-989X.7.2.178.
    1. Little RJ, Yau LHY. Statistical techniques for analyzing data from prevention trials: treatment of no-shows using Rubin's causal model. Psychol Methods. 1998;3(2):147–159. doi: 10.1037/1082-989X.3.2.147.
    1. Allison PD. Missing Data. Thousand Oaks: Sage Publications, Inc.; 2002.
    1. Hedeker D, Gibbons RD. Application of random-effects pattern-mixture models for missing data in longitudinal studies. Psychol Methods. 1997;2(1):64–78. doi: 10.1037/1082-989X.2.1.64.
    1. Little RJA. Pattern-mixture models for multivariate incomplete data. J Am Stat Assoc. 1993;88(421):125–134.
    1. Merlo J, Chaix B, Ohlsson H, Beckman A, Johnell K, Hjerpe P, Rastam L, Larsen K. A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena. Epidemiol Community Health. 2006;60(4):290–297. doi: 10.1136/jech.2004.029454.
    1. MacKinnon DP, Dwyer JH. Estimating mediated effects in prevention studies. Eval Rev. 1993;17(2):144–158. doi: 10.1177/0193841X9301700202.
    1. MacKinnon DP. Introduction to statistical mediation analysis. Mahwah, NJ: Erlbaum; 2008.
    1. Aiken LS, West SG. Multiple regression: testing and interpreting interactions. Newbury Park: Sage Publications; 1991.
    1. Jaccard J, Turrisi R, Wan CK. Interaction effects in multiple regression. Thousand Oaks: Sage Publications; 1990.
    1. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276(15):1253–1258. doi: 10.1001/jama.1996.03540150055031.
    1. Braithwaite RS, Nucifora KA, Yiannoutsos CT, Musick B, Kimaiyo S, Diero L, Bacon MC, Wools-Kaloustian K. Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives? J Int AIDS Soc. 2011;14:38. doi: 10.1186/1758-2652-14-38.
    1. Braithwaite RS, Fiellin DA, Nucifora K, Bryant K, Roberts M, Kim N, Justice AC. Evaluating interventions to improve antiretroviral adherence: how much of an effect is required for favorable value? Value Health. 2010;13(5):535–542. doi: 10.1111/j.1524-4733.2010.00714.x.
    1. Braithwaite RS, Roberts MS, Chang CC, Goetz MB, Gibert CL, Rodriguez-Barradas MC, Shechter S, Schaefer A, Nucifora K, Koppenhaver R, et al. Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model. Ann Intern Med. 2008;148(3):178–185. doi: 10.7326/0003-4819-148-3-200802050-00004.
    1. Braithwaite RS, Shechter S, Roberts MS, Schaefer A, Bangsberg DR, Harrigan PR, Justice AC. Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation. J Antimicrob Chemoth. 2006;58(5):1036–1043. doi: 10.1093/jac/dkl386.
    1. Braithwaite RS, Justice AC, Chang CC, Fusco JS, Raffanti SR, Wong JB, Roberts MS. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am J Med. 2005;118(8):890–898. doi: 10.1016/j.amjmed.2004.12.034.
    1. Braithwaite RS, Shechter S, Chang CC, Schaefer A, Roberts MS. Estimating the rate of accumulating drug resistance mutations in the HIV genome. Value Health. 2007;10(3):204–213. doi: 10.1111/j.1524-4733.2007.00170.x.
    1. Braithwaite RS, Roberts MS, Justice AC. Incorporating quality of evidence into decision analytic modeling. Ann Intern Med. 2007;146(2):133–141. doi: 10.7326/0003-4819-146-2-200701160-00008.
    1. Braithwaite RS, Rosen AB. Linking cost sharing to value: an unrivaled yet unrealized public health opportunity. Ann Intern Med. 2007;146(8):602–605. doi: 10.7326/0003-4819-146-8-200704170-00011.
    1. Saitz R. Clinical practice. Unhealthy alcohol use. N Engl J Med. 2005;352(6):596–607. doi: 10.1056/NEJMcp042262.
    1. Keebler D, Revill P, Braithwaite S, Phillips A, Blaser N, Borquez A, Cambiano V, Ciaranello A, Estill J, Gray R, et al. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models. Lancet Glob Health. 2014;2(1):e35–e43. doi: 10.1016/S2214-109X(13)70048-2.
    1. Kessler J, Myers JE, Nucifora KA, Mensah N, Kowalski A, Sweeney M, Toohey C, Khademi A, Shepard C, Cutler B, et al. Averting HIV infections in new York City: a modeling approach estimating the future impact of additional behavioral and biomedical HIV prevention strategies. PLoS One. 2013;8(9) doi: 10.1371/journal.pone.0073269.
    1. Kessler J, Myers JE, Nucifora KA, Mensah N, Toohey C, Khademi A, Cutler B, Braithwaite S. Evaluating the impact of prioritization of antiretroviral pre-exposure prophylaxis in New York. AIDS. 2014;28(18):2683–2691. doi: 10.1097/QAD.0000000000000460.
    1. Braithwaite R, Nucifora KA, Toohey C, Kessler J, Uhler LM, Mentor SM, Keebler D, Hallett T. How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa? AIDS. 2014;28(Suppl 1):S73–S83. doi: 10.1097/QAD.0000000000000110.
    1. Erlen JA, Cha ES, Kim KH, Caruthers D, Sereika SM. The HIV medication taking self-efficacy scale: psychometric evaluation. J Adv Nurs. 2010;66(11):2560–2572. doi: 10.1111/j.1365-2648.2010.05400.x.
    1. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14(1):1–24. doi: 10.1080/08870449908407311.
    1. Anderson LA, Dedrick RF. Development of the trust in physician scale: a measure to assess interpersonal trust in patient-physician relationships. Psychol Rep. 1990;67(3f):1091–1100. doi: 10.2466/pr0.1990.67.3f.1091.
    1. Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28(1):47–58. doi: 10.1097/00042560-200109010-00008.
    1. LaVeist TA, Isaac LA, Williams KP. Mistrust of health care organizations is associated with underutilization of health services. Health Serv Res. 2009;44(6):2093–2105. doi: 10.1111/j.1475-6773.2009.01017.x.
    1. Balfour L, Tasca GA, Kowal J, Corace K, Cooper CL, Angel JB, Garber G, Macpherson PA, Cameron DW. Development and validation of the HIV medication readiness scale. Assessment. 2007;14(4):408–416. doi: 10.1177/1073191107304295.
    1. Sherbourne CD, Stewart AL. The Mos social support survey. Soc Sci Med. 1991;32(6):705–714. doi: 10.1016/0277-9536(91)90150-B.
    1. DiMatteo MR, Hays RD, Gritz ER, Bastani R, Crane L, Elashoff R, Ganz P, Heber D, McCarthy W, Marcus A. Patient adherence to cancer control regimens: scale development and initial validation. Psychol Assessment. 1993;5(1):102–112. doi: 10.1037/1040-3590.5.1.102.
    1. National Institute on Drug Abuse: Seek, Test, Treat and Retain for Vulnerable Populations: Data Harmonization Measure (Social Support Subscale). . Accessed 25 June 2015.
    1. Rintamaki LS, Davis TC, Skripkauskas S, Bennett CL, Wolf MS. Social stigma concerns and HIV medication adherence. AIDS Patient Care STDs. 2006;20(5):359–368. doi: 10.1089/apc.2006.20.359.
    1. Rollnick S. Readiness, importance, and confidence: Critical conditions of change in treatment. In: Heather WRMN, editor. Treating addictive behaviors. 2nd edn. New York: Plenum Press; 1998. p. 49–60.
    1. Shapiro M, Morton S, McCaffrey D, Senterfitt J, Fleishman J, Perlman J, Athey L, Keesey J, Goldman D, Berry S, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV cost and services utilization study. JAMA. 1999;281(24):2305–2315. doi: 10.1001/jama.281.24.2305.
    1. National Institute on Drug Abuse: Seek, Test, Treat and Retain for Vulnerable Populations: Data Harmonization Measure (Service Utilization Measure). . Accessed 25 June 2015.
    1. National Institute on Drug Abuse: Seek, Test, Treat and Retain for Vulnerable Populations: Data Harmonization Measure (Drug and Alcohol Use Measure). . Accessed 21 Sept 2015.
    1. Radloff LS. The CES-D scale a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385–401. doi: 10.1177/014662167700100306.
    1. Balfour L, Kowal J, Tasca GA, Cooper CL, Angel JB, Macpherson PA, Garber G, Beique L, Cameron DW. Development and psychometric validation of the HIV treatment knowledge scale. AIDS Care. 2007;19(9):1141–1148. doi: 10.1080/09540120701352241.
    1. Huba GJ, Melchior LA. Staff of the measurement group, HRSA/HAB's SPNS cooperative agreement steering committee. Module 11: client satisfaction survey. Culver City: The Measurement Group; 1997.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する